Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0049 • ACR Convergence 2022
IL-18 Receptor-α Signaling Pathway Contributes to Autoantibody-induced Arthritis via Neutrophil Recruitment
Shinjiro Kaieda and Tomoaki Hoshino, Kurume University School of Medicine, Kurume, Japan
Background/Purpose: We have previously reported that IL-18 levels in the lungs, serum and bronchoalveolar lavage fluid (BALF) were increased in patients with idiopathic pulmonary lung…
Abstract Number: 0093 • ACR Convergence 2022
Comparison of Faculty and Fellow Prescribing Patterns for Rheumatoid Arthritis in an Urban, Academic Hospital
Ana Valle¹, Xianhong Xie², Don-Andre Jackson³ and Irene Blanco⁴, ¹Montefiore Medical Center, New York, NY, ²Department of Epidemiology & Population Health/Albert Einstein College of Medicine, Bronx, NY, ³Griffin Health, Stamford, CT, ⁴Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Timely initiation of DMARDs in rheumatoid arthritis (RA) is necessary to prevent significant morbidity and mortality. Yet, patients from marginalized groups are less likely…
Abstract Number: 0205 • ACR Convergence 2022
Virtually Training Peer Coaches to Use Motivational Interviewing Skills: Processes from a Rheumatoid Arthritis Intervention Training Program
Mackenzie Brown¹, Yuliana Domínguez Páez², Assem Jabri³, Geyanne Lui⁴, Joan Weiner³, Aberdeen Allen⁵, Tien Sydnor-Campbell⁶, Shelley fritz³, Megan Creasman⁷, Shanthini Kasturi⁸, Monika Safford³ and Iris Navarro-Millan³, ¹Weill Cornell Medicine, Brooklyn, NY, ²Weill Cornell Medicine, Bronx, NY, ³Weill Cornell Medicine, New York, NY, ⁴Albert Einstein College of Medicine, New York, NY, ⁵Weill Cornell Medicine, Parlin, ⁶Weill Cornell Medicine, Philedelphia, ⁷NYP-Weill Cornell, New York, NY, ⁸Tufts Medical Center, Boston, MA
Background/Purpose: Peer coaching interventions are effective in helping individuals with chronic conditions understand and manage their disease. Most peer coach training programs occur in person,…
Abstract Number: 0253 • ACR Convergence 2022
Evaluation of Patients with Rheumatoid Arthritis in Teleconsultation During the First Wave of the COVID-19 Pandemic
Jérôme Avouac¹, Anna Molto², Camelia Frantz³, sarah wanono³, elise descamps⁴, olivier fogel⁴, Alice Combier⁵, lucile poiroux⁵, Corinne MIceli⁶ and Yannick Allanore⁷, ¹University of Paris, Paris, France, ²Rheumatology Department, Hôpital Cochin,Assistance Publique- Hôpitaux de Paris, Paris, France, ³Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁴Hôpital Cochin, AP-HP Centre - Université de Paris Cité, Paris, France, ⁵Hôpital Cochin, AP-HP.Centre - Université Paris Cité, Paris, France, ⁶APHP, Paris, France, ⁷Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France
Background/Purpose: The sudden emergence of SARS-CoV-2 onto the world stage has accelerated a major change in the management of patients with chronic rheumatic diseases and…
Abstract Number: 0269 • ACR Convergence 2022
Practical Cut-off Points for Using the Rheumatoid Arthritis Impact of Disease (RAID) Questionnaire in Remote Consult Triage
Marijke van den Dikkenberg¹, Martijn Kuijper², Marc Kok¹, Deirisa Lopes Barreto² and Angelique Weel¹, ¹Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam, Netherlands, ²Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam
Background/Purpose: In modern Rheumatoid Arthritis (RA) care remote consults (via phone or video call) are increasing. Whereas the Disease Activity Scores (DAS) requires a patient…
Abstract Number: 0287 • ACR Convergence 2022
Association Between Short-Term Response to Upadacitinib Treatment and Long-Term Clinical Outcomes in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy
Christina Charles-Schoeman¹, Roy Fleischmann², Stephen Hall³, Arthur Kavanaugh⁴, Andrea Rubbert-Roth⁵, Ryan DeMasi⁶, Sara Penn⁶, Andrew Garrison⁶, Samuel Anyanwu⁶, Radames Sierra-Zorita⁷ and Ricardo Xavier⁸, ¹Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ²University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, ³Emeritus Research and Monash University, Melbourne, Australia, ⁴University of California San Diego, La Jolla, CA, ⁵Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, ⁶AbbVie, Inc., North Chicago, IL, ⁷University of Puerto Rico, San Juan, Puerto Rico, ⁸Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Background/Purpose: Early predictors of response to treatment with upadacitinib (UPA), an oral Janus kinase inhibitor, could help to optimize a treat-to-target approach in patients with…
Abstract Number: 0303 • ACR Convergence 2022
Effectiveness of Upadacitinib in the Treatment of Rheumatoid Arthritis: Analysis of 6-Month Real-World Data from the United Rheumatology Normalized Integrated Community Evidence (UR-NICETM) Database
Allan Gibofsky¹, Mark Pearson², Andrew Concoff³, Anna K Shmagel⁴, Patrick Zueger⁴, Yanna Song⁴, Lauren Smith⁵ and Grace Wright⁶, ¹Weill Cornell Medical College and Hospital for Special Surgery, New York, NY, ²West Suburban Center for Arthritis, Milwaukee, WI, ³United Rheumatology, Hauppauge, NY, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Chicago, IL, ⁶Grace C Wright MD PC, Association of Women in Rheumatology, New York, NY
Background/Purpose: The efficacy of upadacitinib (UPA), an oral Janus kinase inhibitor (JAKi), in the treatment of rheumatoid arthritis (RA) has been demonstrated in the phase…
Abstract Number: 0501 • ACR Convergence 2022
Single-molecule Spatial Transcriptomic Analysis Reveals Distinct Cellular Networks in Rheumatoid Arthritis Synovia
Roopa Madhu¹, Kartik Bhamidipati¹, Nghia Millard², Michelle Curtis², Ye Cui³, Youngmi Kim³, Ellen Gravallese⁴, Soumya Raychaudhuri¹, Michael Brenner⁴, ilya Korsunsky¹ and Kevin Wei⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Boston, MA, ³Nanostring Technologies Inc., Seattle, WA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Chronic joint inflammation in rheumatoid arthritis (RA) arises from the interactions of many cell types. Single-cell transcriptomic profiling of RA joints has identified novel…
Abstract Number: 0578 • ACR Convergence 2022
Interleukin-6 Trans-Signaling Induces Synovial Fibroblast Invasiveness by Utilizing Ets2 Protein
Anil Singh, Paul Panipinto, Farheen Sultan Shaikh and Salahuddin Ahmed, Washington State university, Spokane, WA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease with a complex interplay of synovial cells and soluble factors that create the signatures of chronic inflammation…
Abstract Number: 0601 • ACR Convergence 2022
Occupational Inhaled Agents Constitute Major Risk Factors for Rheumatoid Arthritis, Particularly in the Context of Genetic Predisposition and Smoking
Bowen Tang¹, Qianwen Liu², Anna Ilar³, Pernilla Wiebert², Sara Hägg¹, Leonid Padyukov², Lars Klareskog², Lars Alfredsson² and Xia Jiang², ¹Karolinska Institutet, Solna, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³The National Board of Health and Welfare, Stockholm, Sweden
Background/Purpose: The lung is recognized as a primary site in the induction of rheumatoid arthritis (RA). Our study aims to assess the effect of common…
Abstract Number: 0619 • ACR Convergence 2022
Differences Between Patients in Remission with Active Rheumatoid Arthritis by Histological and Molecular Comparisons
Selina Ohl¹, Klaus Frommer², Markus Rickert³, Stefan Rehart⁴, Ulf Müller-Ladner⁵ and Elena Neumann⁶, ¹Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, ²Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, ³Dept. of Orthopaedics and Orthopaedic Surgery, University Hospital Giessen and Marburg, Giessen, Germany, Gießen, Germany, ⁴Agaplesion Markus Hospital, Dpt of Orthopaedics and Trauma Surgery, Frankfurt, Germany, ⁵JLU Campus KK, Bad Nauheim, Germany, ⁶JLU Gießen, Campus Kerckhoff, Bad Nauheim, Germany
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease, whose inflammatory processes in the synovium lead to the destruction of cartilage and bone. Although there…
Abstract Number: 0722 • ACR Convergence 2022
Cardiovascular and Oncologic Outocomes of Anti-TNF Alfa and JAK Inhibitors in Patients with Rheumatoid and Psoriatic Arthritis. Real World Data and Insights of BIOBADASAR 3.0 Registry
Alejandro Brigante¹, Rosana Quintana², Carolina Isnardi³, Karen Roberts⁴, Gimena Gomez⁵, Maria Haye Salinas⁶, Enrique Soriano⁷, Guillermo Pons-Estel⁸, Maria De la Vega⁸, Osvaldo kerzberg⁷, Julieta Gamba⁷, Anastasia Secco⁹, Gustavo Citera¹⁰, Cesar Graf⁷, Veronica Savio¹¹, Maria de los Angeles Gallardo⁷, Nora Aste⁷, Mercedes A Garcia¹², Gustavo Casado⁷, Carla Gobbi⁷, Graciela Gomez⁷, Joan Manuel Dapeña¹³, Guillermo Berbotto⁷, Malena Viola⁷, Jonathan Rebak⁷, Diana Dubinsky⁷, Veronica Saurit¹⁴, Ingrid Petkovic⁷, Ana Bertoli⁷, Erika Catay⁷, C Leoni⁷, Ida Elena Exeni⁷, Bernardo Pons-Estel¹⁵, Sergio Paira⁷, GH Bovea Castelblanco⁷, Mercedes De la Sota⁷, Dora Pereira⁷, Gustavo Medina⁷, Amelia Granel⁷, Maria s Larroude⁷, Analia Patricia Alvarez⁷, Santiago Agüero¹⁶, Cecilia Pisoni¹⁷, Monica Sacnun⁷ and Edson Velozo¹⁸, ¹UNISAR, Lobos, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas. Grupo Oroño (GO CREAR) and Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ³SAR-COVID Coordinator, Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ⁴UNISAR, Rosario, Argentina, ⁵Sanatorio Guemes, Buenos Aires, Argentina, ⁶UNLAR, La Rioja, Argentina, ⁷On behalf of the BIOBADASAR 3.0 registry, Buenos Aires, Argentina, ⁸Argentine Society of Rheumatology, Buenos Aires, Argentina, ⁹Rivadavia Hospital, Buenos Aires, Argentina, ¹⁰Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, ¹¹Hospital Córdoba; Consultora Integral de Salud CMP, Cordoba, Argentina, ¹²HIGA San Martin, La Plata, Argentina, ¹³Hospital General de Agudos Dr. Enrique Tornu, Buenos Aires, Argentina, ¹⁴Hospital Privado Universitario, Cordoba, Argentina, ¹⁵Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ¹⁶Centro de Rehabilitación Dr Mauricio Figueroa, Catamarca, Argentina, ¹⁷CEMIC- Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina, ¹⁸SAR COVID Investigator, Caba
Background/Purpose: Major adverse cardiovascular events (MACE) and neoplasms are a concern in autoimmune diseases. RA and PsA are diseases where inflammation plays a key role…
Abstract Number: 0786 • ACR Convergence 2022
Humoral and T-cell Responses to SARS-CoV-2 Vaccination in Patients with Rheumatoid Arthritis
Carolina A Isnardi¹, Osvaldo Luis Cerda¹, MARGARITA LANDI², Leonel Cruces³, Emilce Edith Schneeberger¹, Claudia Calle montoro², Maria Agustina Alfaro⁴, Brian Manases roldan⁴, Andrea Belen Gomez Vara¹, Pamela Giorgis⁴, Roberto Alejandro Ezquer⁴, María G Crespo Rocha⁴, Camila R Reyes Gómez⁴, maria de los angeles correa⁴, Marcos Rosemffet⁵, Virginia Carrizo Abarza⁴, Santiago Catalan Pellet⁶, Miguel Perandones⁴, Cecilia Reimundes⁷, Yesica Longueira³, Gabriela Turk³, María Florencia Quiroga³, Natalia Laufer³, Rosana Quintana⁸, Maria De la Vega⁹, Nicolás Kreplak¹⁰, Marina Pifano¹⁰, Pablo Maid², Guillermo Pons-Estel¹¹ and Gustavo Citera¹, ¹Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, ²Austral University Hospital, Rheumatology Department, Buenos Aires, Argentina, ³Universidad de Buenos Aires. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS). Facultad de Medicina, Buenos Aires, Argentina, ⁴Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, ⁶Austral University Hospital, Rheumatology Department, Lincoln, Argentina, ⁷Austral University Hospital, Rheumatology Department, Pilar, Argentina, ⁸Centro Regional de Enfermedades Autoinmunes y Reumáticas. Grupo Oroño (GO CREAR) and Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ⁹Argentine Society of Rheumatology, Buenos Aires, Argentina, ¹⁰Ministry of Health of the Province of Buenos Aires, Buenos Aires, Argentina, ¹¹CREAR, Rosario, Argentina
Background/Purpose: Patients with immune mediated diseases achieve lower seroconversion rates to COVID19 vaccines compared to healthy controls, which is why these patients are a prioritized…
Abstract Number: 0891 • ACR Convergence 2022
Rheumatoid Arthritis and the Rheumatic Disease Comorbidity Index (RDCI): Its Impact on Disease Activity
Sultana Abdulaziz¹, Suzan Attar², Renad Ahmed², Hamza Fida², Omar Bokhary², Anas Alyazidi² and Abdulelah Abumohssin², ¹King Fahad Hospital, Jeddah, Saudi Arabia, ²King Abdulaziz University, Jeddah, Saudi Arabia
Background/Purpose: Comorbid conditions in the setting of rheumatoid arthritis (RA) play an important role in predicting disease activity and functional impairment (1). Application of a…
Abstract Number: 0907 • ACR Convergence 2022
Identifying Trajectories of Remission in Patients with Rheumatoid Arthritis Treated in a Tertiary Care Centre
Imke Redeker¹, Nils Gildemeister², Ioana Andreica³, David Kiefer⁴, Xenofon Baraliakos⁵, Juergen Braun⁴ and Uta Kiltz⁴, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Bochum, Germany, ²Ruhr University Bochum, Bochum, Germany, ³Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: The main goal of treatment for patients (pts) with rheumatoid arthritis (RA) is remission to preserve physical function and prevent radiographic damage. However, less…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].